GlassScriptPhysician profile
Michael Aron Dixon
NPI 1104478668
$747.47
in general payments reported to CMS, 2019-2025
12 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $90.03 · 2022: $283 · 2023: $166 · 2024: $47.39 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $374.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $171.78 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $158.46 | 2022-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $105.59 | 2022-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $67.75 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $51.98 | 2022-2023 | Rexulti |
| Indivior INC. | $43.83 | 2022-2023 | Perseris |
| Noven Therapeutics, LLC | $38.37 | 2022-2024 | Secuado, Xelstrym |
| Corium, LLC | $24.94 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.12 | 2022 | |
| Janssen Pharmaceuticals, INC | $23.13 | 2021 | |
| Idorsia Pharmaceuticals US INC | $21.39 | 2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $16.13 | 2023 | Fanapt, Hetlioz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dixon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.